Press Release

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 RPG LIFE SCIENCES Email: info@rpglifesciences.com www.rpglifesciences.com CIN: 124232MH2007PLC169354 July 29, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs /Madam, Sub: Press Release Please find enclosed herewith a copy of press release titled as “RPG Life Sciences Announces Strategic API Initiative to Accelerate Next Phase of Growth”. Kindly take the above on record. Thanking you, Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head- Legal & Company Secretary Encl: as above An q»R?G Company RPG Life Sciences Announces Strategic API Initiative to Accelerate Next Phase of Growth AP/ business to be transferred to wholly owned subsidiary RPG Active Pharma; India Life Sciences Fund managed by lnvAscent to invest in RPG Active Pharma; RPG Active Pharma to acquire Actis Generics. Key Highlights • RPG Life Sciences executes agreement to transfer its API business on a slump sale basis to its wholly owned subsidiary, RPG Active Pharma Limited. • RPG Active Pharma to raise an initial amount upto INR 243 crore from funds managed by lnvAscent. • RPG Active Pharma to acquire 100% equity share capital of Actis Generics Private Limited (Actis). Mumbai, 29 July 2026: RPG Life Sciences Limited ("RPG Life Sciences" or "RPG LS") today announced the execution of a Business Transfer Agreement for the transfer of the Company's Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited ("RPG Active Pharma" or "RPGAP"), a wholly owned subsidiary of RPG Life Sciences, as a going concern on a slump sale basis. The proposed transfer is part of RPG Life Sciences' strategy to create a focused API business with dedicated capital, sharper management attention and greater strategic flexibility, while the Company also continues to build its formulations business. This business has been created at a time when the global pharmaceutical supply chains are undergoing structural realignment and India is increasingly emerging as a preferred destination for reliable, high-quality API manufacturing. The Company has entered into an investment agreement to forge a strategic partnership with Inv Ascent, a healthcare-focused private equity investor, through an investment in RPG Active Pharma. The partnership brings together RPG Life Sciences' pharmaceutical experience, manufacturing capabilities and execution track record with lnvAscent's 20-years' experience of investing in and scaling pharma businesses. Accordingly, funds managed by lnvAscent will make an initial investment of an amount upto Rs. 243 er. in RPG Active Pharma. The agreement envisages investments by the Company and lnvAscent upto Rs. 700 er. in RPGAP in tranches. The investment is expected to provide RPG Active Pharma with the capital and strategic support required to strengthen manufacturing infrastructure, expand the product portfolio, enhance process development capabilities and pursue organic and inorganic growth opportunities. In addition, the RPG Active Pharma has also executed a Share Purchase Agreement for acquisition of 100% equity share capital of Actis Generics Private Limited -an API manufacturing company based in Visakha patnam. The proposed acquisition is expected to expand RPG Active Pharma's manufacturing base, broaden its operating platform and support its strategic growth objectives. The investment by India Life Sciences Fund -a life sciences focused fund - and the proposed acquisition of Actis Generics are intended to establish RPG Active Pharma as a focused API manufacturer for the next phase of RPG Life Sciences' API growth. RPG AP will focus on augmenting its manufacturing capabilities, expanding its API portfolio and serving customers across domestic and international markets with a strong emphasis on quality, reliability and long-term partnerships. The transactions are subject to customary regulatory approvals and pre-closing conditions. Commenting on the development, Ashok Nair, Managing Director, RPG Life Sciences, said: "Building a meaningful and scalable presence in AP/s has been a strategic priority for RPG Life Sciences. RPG Active Pharma gives us a focused business to pursue this opportunity with greater speed, discipline and scale. We are pleased to partner with lnvAscent, whose pharma investing experience and long-term partnership approach complements our vision for the business. The proposed acquisition of Actis Generics further strengthens this business and supports our ambition to build a high-quality AP/ business with expanded manufacturing capabilities, a broader product portfolio and the ability to create sustainable value for all stakeholders." Commenting on the partnership, Dr. Jeevak Gupta, Managing Director, lnvascent, said: "We are excited to partner with RPG Life Sciences in building RPG Active Pharma into a differentiated AP/ business. RPG Life Sciences has established pharmaceutical capabilities, a strong operating foundation and e clear ambition to scale its AP/ business. We believe RPG AP is well positioned to benefit from the long-term growth opportunity in high-quality AP/ manufacturing, and we look forward to supporting the business through capital, strategic guidance and our healthcare sector experience." Khaitan & Co. acted as the legal counsel and structuring advisor to RPG group for the investment transaction. o3 Capital acted as an exclusive financial advisor, Quillan Partners acted as legal counsel and Deloitte undertook financial due diligence on the acquisition of Actis by RPG Active Pharma. About RPG Life Sciences Limited RPG Life Sciences Limited, part of RPG Group, is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APls. The Company develops, manufactures and markets a wide range of quality and affordable medicines and remains focused on innovation, operational excellence and sustainable long-term growth. About RPG Active Pharma Limited RPG Active Pharma Limited is a subsidiary of RPG Life Sciences established to build a focused API business with capabilities across product development, manufacturing and commercialization. RPG Active Pharma will focus on strengthening manufacturing, expanding its product portfolio and pursuing strategic opportunities to build a diversified API platform serving domestic and international customers. About RPG Group (www.rpggroup.com} RPG Group, established in 1979, is one of India's fastest-growing business groups with a turnover of US$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation Led technology businesses. About lnvascent Established in 2005, lnvAscent is India's leading life sciences-focused private equity firm with~ USO 850 million in capital raised to date and investments in 39 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and health tech. Contacts: RPG Life Sciences Contacts: lnvascent Media Contact: Sunaina Jairath Jeevak Gupta Mobile: +91 9811645243 Mobile: +91 9741536677 E-mail: sunaina@rpg.in E-mail: jeevak.gupta@invascent.com